Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company has added two new patent allowances to its intellectual property portfolio for its microRNA platform technology. With these new allowances, Rosetta Genomics has 64 granted or allowed patents and 33 patents pending.
